My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
131.06
-1.25 (-0.94%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
49
50
Next >
FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use
June 23, 2022
Via
Benzinga
Global Interferon Beta Drugs Market | Key Players are Biogen, Merck, Novartis, Bayer, Faron Pharmaceuticals, and other prominent players
June 23, 2022
Global Interferon Beta Drugs Market | Key Players are Biogen, Merck, Novartis, Bayer, Faron Pharmaceuticals, and other prominent players The market size of the Global Interferon Beta Drugs Market in...
Via
iCrowdNewswire
Global Radioligand Therapy Market | Key Players are Johnson & Johnson Services, Inc., Pfizer Inc., Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Amneal Pharmaceuticals LLC, Novartis International AG and many more.
June 23, 2022
Global Radioligand Therapy Market | Key Players are Johnson & Johnson Services, Inc., Pfizer Inc., Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Amneal Pharmaceuticals LLC, Novartis...
Via
iCrowdNewswire
Precision BioSciences (DTIL) Stock Treks Higher on Novartis Deal
June 22, 2022
DTIL stock is advancing in early trading today after Precision BioScience announced a partnership with Novartis, a leading drug maker.
Via
InvestorPlace
Why Precision BioSciences Shares Are Surging Today
June 22, 2022
Via
Benzinga
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
June 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
NYSE:NVS Investor Alert: Investigation over Possible Securities Laws Violations by Novartis AG
June 17, 2022
San Diego, CA -- (SBWIRE) -- 06/17/2022 -- Novartis AG is under investigation concerning potential securities laws violations in connection with certain financial statements.
Via
SBWire
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
June 13, 2022
Via
Benzinga
Crews Control Names Barbara Kittridge President, Andrea Keating Moves to CEO
June 09, 2022
Crews Control promotes Barbara Kittridge to President.
Via
Newswire.com
Sylvester Feddes joins the 2022 Leading Entrepreneurs of the World Conference
June 08, 2022
The Country President of Novartis Colombia will speak at 1BusinessWorld’s Leading Entrepreneurs of the World Conference about leading diversity and inclusion in a virtual environment
Via
News Direct
Pfizer's Ibrance Fails To Extend Overall Survival In Newly Diagnosed Breast Cancer Setting
June 06, 2022
Via
Benzinga
NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm
June 02, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
New effort to standardize cardiovascular care in Mexico, address gaps in care
June 02, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
2021 R&D Spending and Intensity Benchmarks
June 06, 2022
VIRGINIA BEACH, Va. - June 6, 2022 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D...
Via
PRLog
Topics
Supply Chain
NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm
June 01, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novartis AG (NVS) on Behalf of Investors
June 01, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Novartis AG (NVS) on Behalf of Investors
May 31, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Novartis AG (NVS) on Behalf of Investors
May 31, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May 31, 2022
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
Via
Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
May 26, 2022
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...
Via
FinancialNewsMedia
6 Dividend Stocks With High Yields and Low P/E Ratios
May 23, 2022
These 6 dividend stocks have yields greater than 2.5% and P/E ratios lower than 16x with a positive earnings growth forecast for 2023.
Via
InvestorPlace
Online shop Etalaze announces shift to a new domain www.Etalaze.biz
May 20, 2022
Via
AB Newswire
Analyzing Novartis's Short Interest
May 17, 2022
Novartis's (NYSE:NVS) short percent of float has risen 3.57% since its last report. The company recently reported that it has 6.56 million shares sold short, which is 0.29% of all...
Via
Benzinga
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities
May 17, 2022
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach...
Via
iCrowdNewswire
Current Report: Novartis (NVS)
May 17, 2022
Novartis’s price per share was $87.81 as of yesterday's market close. One year ago its price was $88.85.
Via
Talk Markets
Asia-Pacific Anti-Inflammatory Therapeutics Market Qualitative Insights on Application & Outlook by Share, Future Growth
May 16, 2022
Asia-Pacific Anti-Inflammatory Therapeutics Market Qualitative Insights on Application & Outlook by Share, Future Growth Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR...
Via
iCrowdNewswire
Topics
Intellectual Property
5 Value Stocks In The Healthcare Sector
May 16, 2022
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
3 Undervalued Stocks to Buy Before You Sell in May and Go Away
May 13, 2022
If you really decide to sell in May and go away, you may miss out some profits from these undervalued stocks to buy.
Via
InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
May 12, 2022
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
Via
Investor's Business Daily
Surgical Equipment Market Top Companies, Business Growth & Investment Opportunities, Share
May 12, 2022
Surgical Equipment Market Top Companies, Business Growth & Investment Opportunities, Share The global surgical equipment market valued at $31,722.30 million in 2019 and is estimated to reach $44,448.58...
Via
iCrowdNewswire
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
49
50
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.